Trials / Completed
CompletedNCT03179748
Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
Non-interventional, Multi-Centre, Post-Authorisation Safety Study With Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The trial is conducted in North America. The aim of the trial is to assess the safety of turoctocog alfa under conditions of routine clinical care in patients with haemophilia A in Mexico
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | turoctocog alfa | Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician |
Timeline
- Start date
- 2018-06-20
- Primary completion
- 2021-06-16
- Completion
- 2021-06-16
- First posted
- 2017-06-07
- Last updated
- 2021-11-15
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT03179748. Inclusion in this directory is not an endorsement.